SCYNEXIS: SCYNEXIS Begins Phase 1 Trial Of SCY-247 For Severe Invasive Fungal Infections

(RTTNews) - SCYNEXIS, Inc. (SCYX), a biotechnology company specializing in treatments for drug-resistant infections, has initiated dosing in its Phase 1 clinical trial for SCY-247, a second-generation antifungal candidate.